Everything drug pricing and policy, every day
Plus a look at how MFN is impacting drug launches in Canada
Plus important context around data suggesting employers are fleeing the “Big Three” PBMs
And Lilly and Novo weigh in on the early days of CMS’ Bridge program
And four studies examining everything from 340B to orphan drug incentives
